Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer

Authors: Chun-Hua Xu, Lan Cao, Xiu-Wei Zhang, Jun Yan, Li-Ke Yu

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

B7-H4, a member of the inhibitory B7 family, can restrain T cell proliferation, activation, and cytokine secretion and may be involved in immune evasion in cancer patients. This study aimed to evaluate the diagnostic and prognostic value of pleural effusion levels of soluble B7-H4 (sB7-H4) in lung cancer patients with malignant pleural effusion (MPE). Pleural effusion samples were collected from 98 lung cancer patients with malignant effusion and from 60 patients with nonmalignant pleural effusion. Pleural effusion concentrations of sB7-H4 were measured using sandwich enzyme-linked immunosorbent assay. Malignant effusion exhibited higher sB7-H4 levels than those in nonmalignant effusion (P < 0.01). Lung cancer patients with pleural effusion sB7-H4 levels below 35.8 ng/ml had a longer overall survival than those with higher levels (P < 0.05). By multivariate analysis, pleural effusion sB7-H4 was an independent prognostic factor in patients with MPE. In conclusion, measurement of sB7-H4 might be a useful diagnostic and prognostic value for MPE patients.
Literature
1.
Kasahara K, Shibata K, Shintani H, Iwasa K, Sone T, et al. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. Anticancer Res. 2006;26:1495–9.PubMed
2.
Cheng D, Liang B, Li YH. Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion. Asian Pac J Cancer Prev. 2012;13:505–9.CrossRefPubMed
3.
Xu CH, Zhan P, Yu LK, Zhang XW. Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions. Tumour Biol. 2014;35:1599–603.CrossRefPubMed
4.
Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest. 2004;125:987–9.CrossRefPubMed
5.
6.
Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757–63.CrossRefPubMed
7.
Su WC, Lai WW, Chen HH, Hsiue TR, Chen CW, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology. 2003;64:18–24.CrossRefPubMed
8.
Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65:371–6.CrossRefPubMed
9.
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.CrossRefPubMed
10.
Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006;66:1570–5.CrossRefPubMed
11.
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.CrossRefPubMed
12.
Quandt D, Fiedler E, Boettcher D, Marsch WC, Seliger B. B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 2011;17:3100–11.CrossRefPubMed
13.
Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005;11:1842–8.CrossRefPubMed
14.
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53:143–51.CrossRefPubMed
15.
Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 2006;100:44–52.CrossRefPubMed
16.
Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103:10391–6.CrossRefPubMedPubMedCentral
17.
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104:19458–63.CrossRefPubMedPubMedCentral
18.
Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, et al. B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60:1047–55.CrossRefPubMed
19.
Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas. 2008;36:200–6.CrossRefPubMed
20.
Jiang J, Zhu Y, Wu C, Shen Y, Wei W, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother. 2010;59:1707–14.CrossRefPubMed
21.
Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102:26–38.CrossRefPubMedPubMedCentral
22.
Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfert RL, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 2008;99:1103–13.CrossRefPubMedPubMedCentral
23.
Simon I, Katsaros D, Rigault de la Longrai I, Massobrio M, Scorilas A, et al. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol. 2007;106:334–41.CrossRefPubMed
24.
Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007;106:112–8.CrossRefPubMed
25.
Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, et al. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008;68:6054–8.CrossRefPubMedPubMedCentral
26.
Arigami T, Uenosono Y, Hirata M, Hagihara T, Yanagita S, Ishigami S, et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol. 2010;102:748–52.CrossRefPubMed
27.
Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67:8900–5.CrossRefPubMed
Metadata
Title
Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer
Authors
Chun-Hua Xu
Lan Cao
Xiu-Wei Zhang
Jun Yan
Li-Ke Yu
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3079-x

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

Differential expression of microRNAs in postoperative radiotherapy sensitive and resistant patients with glioblastoma multiforme

Research Article

Epigenetic inactivation of SOX1 promotes cell migration in lung cancer

Research Article

Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma

Research Article

Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians

Research Article

Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers

Research Article

XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits